Announcements Trials
Browse Landscape

Phase

Phase NA 10Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Gastrointestinal 7Genitourinary 4Thoracic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2267Lung Neoplasms 1050Small Cell Lung Carcinoma 403Adenocarcinoma of Lung 155Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 69Colorectal Neoplasms 69Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Head and Neck Neoplasms 47Ovarian Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 39Stomach Neoplasms 36Prostatic Neoplasms 36Sarcoma 35Esophageal Neoplasms 35Uterine Cervical Neoplasms 34Squamous Cell Carcinoma of Head and Neck 34Adenocarcinoma 34Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplastic Cells, Circulating × Thoracic × Clear all
NCT04648189 2023-10-19

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

The Netherlands Cancer Institute

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡